Can-Tong Liu

Can-Tong Liu

Auto-generated profile, based on publicly available information

Can-Tong Liu

Department of Clinical Laboratory Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Disease Markers
Verified
Journal Article
Open access
PDF file
YXYu-Wei Xu
Yu-Wei Xu
CLCan-Tong Liu
Can-Tong Liu
Xinyi HuangXinyi Huang
Xinyi Huang
LHLi-Sheng Huang
Li-Sheng Huang
YLYu-Hao Luo
Yu-Hao Luo
ELEnmin Li
Enmin Li
Esophageal squamous cell carcinoma (ESCC) remains one of the leading causes of cancer-related mortality around the world. The identification of novel serum biomarkers is required for early detection of ESCC. This study was designed to elucidate whether autoantibodies against STIP1 could be a diagnostic biomarker in ESCC. An enzyme-linked immunosorbent assay was performed to detect serum levels of STIP1 autoantibodies in a training cohort (148 ESCC patients and 111 controls) and a validation cohort (60 ESCC patients and 40 controls). Mann–Whitney’s U test showed that ESCC patients in two cohorts have higher levels of autoantibodies against STIP1 when compared to controls (P<0.001). According to receiver operating characteristic analysis, the sensitivity, specificity, and area under the curve (AUC) of autoantibodies against STIP1 in ESCC were 41.9%, 90.1%, and 0.682 in the training cohort and 40.0%, 92.5%, and 0.710 in the validation cohort, respectively. Moreover, detection of autoantibodies against STIP1 could discriminate early-stage ESCC patients from controls, with sensitivity, specificity, and AUC of 35.7%, 90.1%, and 0.684 in the training cohort and 38.5%, 92.5%, and 0.756 in the validation cohort, respectively. Our findings indicated that autoantibodies against STIP1 might be a useful biomarker for early-stage ESCC detection.

10 July 2021 in Disease Markers
Verified
Journal Article
Open access
PDF file
SYShi-Han Yang
Shi-Han Yang
CLCan-Tong Liu
Can-Tong Liu
CHChao-Qun Hong
Chao-Qun Hong
ZHZe-Yuan Huang
Ze-Yuan Huang
HWHuan-Zhu Wang
Huan-Zhu Wang
YXYu-Wei Xu
Yu-Wei Xu
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are two predominant histological types of nonmelanoma skin cancer (NMSC), lacking effective early diagnostic markers. In this study, we assessed the diagnostic value of autoantibodies against p53, MMP-7, and Hsp70 in skin SCC and BCC. ELISA was performed to detect levels of autoantibodies in sera from 101 NMSC patients and 102 normal controls, who were recruited from the Cancer Hospital of Shantou University Medical College. A receiver operator characteristic curve was used to evaluate the diagnostic value. The serum levels of autoantibodies against p53, MMP-7, and Hsp70 were higher in NMSCs than those in the normal controls (all ). The AUC of the three-autoantibody panel was 0.841 (95% CI: 0.788-0.894) with the sensitivity and specificity of 60.40% and 91.20% when differentiating NMSCs from normal controls. Furthermore, measurement of this panel could differentiate early-stage skin cancer patients from normal controls (AUC: 0.851; 95% CI: 0.793-0.908). Data from Oncomine showed that the level of p53 mRNA was elevated in BCC ( ), and the Hsp70 mRNA was upregulated in SCC ( ). This serum three-autoantibody panel might function in assisting the early diagnosis of NMSC.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
CLCan-Tong Liu
Can-Tong Liu
CHChao-Qun Hong
Chao-Qun Hong
XHXu-Chun Huang
Xu-Chun Huang
ELEnmin Li
Enmin Li
YXYu-Wei Xu
Yu-Wei Xu
YPYu-Hui Peng
Yu-Hui Peng
Esophagogastric junction cancer poses a great threat to human beings both in western countries and East Asia, especially in China and Japan, and its incidence has increased during recent decades. The 5-year survival rate of esophagogastric junction cancer is quite poor compared with that of other gastric cancer sites. Until now, the traditional TNM staging system has been widely used in clinical practice for prognosis. However, the TNM system is based on pathology after surgical resection or radiology using CT and MRI, not on blood markers. Evidently, some research has been reported concentrated on the prognostic value of blood-based markers with the character of non-invasive and non-radioactive in EJA. Hematologic, biochemical and coagulation parameters could be obtained from clinical data and utilized to analyze their prognostic values. Tumor-associated antigens, microRNAs and circulating tumor cells have also been reported in EJC prognosis. In this article, we review research focused on blood-based markers to evaluate their prognostic value in esophagogastric junction cancer, especially its main subtype adenocarcinoma.

15 November 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
CLCan-Tong Liu
Can-Tong Liu
YXYu-Wei Xu
Yu-Wei Xu
HGHong Guo
Hong Guo
CHChao-Qun Hong
Chao-Qun Hong
Xinyi HuangXinyi Huang
Xinyi Huang
YPYu-Hui Peng
Yu-Hui Peng
Can-Tong Liu, Yi-Wei Xu, Hong Guo, Chao-Qun Hong, Xin-Yi Huang, Yu-Hao Luo, Shi-Han Yang, Ling-Yu Chu, En-Min Li, and Yu-Hui Peng. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl19135